Loading
Some harmless bacteria naturally grow in the low-oxygen core of tumours. Engineering them to produce immune-activating drugs turns them into tiny factories inside the tumour.
Attenuated Salmonella and E. coli Nissle strains colonise hypoxic tumour cores selectively, and synthetic biology allows quorum-controlled payload release of STING agonists, CD47 nanobodies or cytokines. Early human experience with intratumoural bacterial therapy exists, and BCG in bladder cancer is a century-old proof that live bacteria can drive anti-tumour immunity. Safety, biocontainment and manufacturing are the real hurdles.
One of the most cited reviews Europe PMC returns for CD47 in Colorectal cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One of the most cited trial reports Europe PMC returns for CD47 in Colorectal cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One of the most cited reviews Europe PMC returns for CD47 in Pancreatic ductal adenocarcinoma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Two bottleneck pages and 32 idea pages on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
Shares Expression and Clinical Significance of CD47 in Colorectal Cancer: A Review, Overcoming immunotherapeutic resistance in PDAC: SIRPα-CD47 blockade, Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer, STING & innate immune agonists.
Shares Intravesical BCG, Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy), Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Cold tumours and the immunosuppressive microenvironment.
Shares STING & innate immune agonists, CD47, Cytokines & engineered cytokines, Cold tumours and the immunosuppressive microenvironment.
Shares Overcoming immunotherapeutic resistance in PDAC: SIRPα-CD47 blockade, CD47, Pancreatic ductal adenocarcinoma.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Cold tumours and the immunosuppressive microenvironment, Pancreatic ductal adenocarcinoma, Colorectal cancer.
Shares STING & innate immune agonists, Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Cold tumours and the immunosuppressive microenvironment.
Shares CD47, Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Cold tumours and the immunosuppressive microenvironment.
Shares STING & innate immune agonists, Cold tumours and the immunosuppressive microenvironment, Colorectal cancer.